EQL Pharma Investor Relations

Press Releases

Change in number of shares and votes in EQL Pharma AB

Regulatory

During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the an...

Mellozzan® (melatonin) launched in the UK

EQL's key product Mellozzan[®] (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan[®] successfully in Germany, among ot...

Se all

Presentations

Interim Report Q1 2025/2026

Year End Report 2024/2025 (in Swedish)

Se all